Multicellular living organisms and unmodified parts thereof and – Nonhuman animal
Reexamination Certificate
2004-07-02
2010-02-16
Kelly, Robert M. (Department: 1633)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
C800S003000, C800S018000, C800S021000, C435S325000, C435S354000, C435S455000
Reexamination Certificate
active
07663017
ABSTRACT:
The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
REFERENCES:
patent: 2003/0101465 (2003-05-01), Lawman et al.
patent: WO 02/059263 (2002-08-01), None
patent: WO 03/006639 (2003-01-01), None
patent: WO 2005/004592 (2005-01-01), None
Rulicke and Hubischer, 2000, Experimental Physiology 85: 589-601.
Holschneider et al., 2001, Int J. Devl. Neuroscience 18:615-618.
Loirat et al (2000, J. immunology 165:4748-4755.
Alexander, Jeff, et al., “Derivation of HLA-A11/KbTransgenic Mice,”Journal of Immunology, vol. 159, No. 10, pp. 4753-4761 (1997).
Baker, Alexander G.H., et al., “Analogues of CTL Epitopes MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope,”Journal of Cancer, vol. 70, pp. 302-309 (1997).
Barra, Claude, et al., “Abrogation of H-2-Restricted CTL Responses and Efficient Recognition of HLA-A3 Molecules in DBA/2 HLA/A24 Responder Mice,”Journal of Immunology, vol. 150, No. 9, pp. 3681-3689, (1993).
Benmohamed, Lbachir, et al., “Induction of CTL Response by a Minimal Epitope Vaccine in HLA A*0201/DR1 Transgenic Mice: Dependence on HLA Class II Restricted THResponse,”Human Immunology, vol. 61, No. 8, pp. 764-779 (2000).
Carmon, Lior, et al., “Novel Breast-Tumor-Associated MUC1 Peptides: Characterization in Db-/- x β Microglobulin (β2m) Null Mice Transgenic for a Chimeric HLA-A2.1/Db-β2 Microglobulin Single Chain,”International Journal of Cancer, vol. 85, pp. 391-397 (2000).
Elliott, Suzanne L., et al., “Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems,”Vaccine, vol. 17, pp. 2009-2019 (1999).
Epstein, Helen, et al., “Expression and Function of HLA-A2.1 in Transgenic Mice,”European Journal of Immunology, vol. 7, pp. 1575-1583 (1989).
Hill, Adrian V.A., “The Immunogenetics of Human Infectious Diseases,”Annual Review of Immunology, vol. 16, pp. 593-616 (1998).
Le, Al-Xuan T., “Cytotoxic T Cell Responses in HLA-A2.1 Transgenic Mice,”J. of Immunology, vol. 142, No. 4, pp. 1366-1371 (1989).
Lustgarten, Joseph et al., “Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice Expressing HLA-A-2.1 and Human CD.8,”Human Immunology, vol. 52, No. 2, pp. 109-118 (1997).
Madson, Lars et al., “Mice lacking all conventional MHC class II genes,”Proceedings of the National Academy of Sciences, vol. 96, pp. 10338-10343 (1999).
Nishimura, Yasuharu et al., “Expression of the Human MHC, HLA-DQW6 Genes Alters the Immune Response in C57BL/6 Mice,”Journal of Immunology, vol. 145, No. 1, pp. 353-360 (1990).
Pajot, Anthony et al., “A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice,”European Journal of Immunology, vol. 34, No. 11, pp. 3060-3069 (2004).
Pajot, Anthony et al., “Comparison of HLA-DRI transgenic mice deficient for murine MHC class II and HLA-DRI transgenic mice expressing endogenous murine MHC class II molecules,”International Immunology, vol. 16, No. 19, pp. 1275-1282 (2004).
Pascolo, Steve, et al., “HLA-A2.1-restricted Education and Cytolytic Activity of CD8* T.Lymphocytes from β2m) HLA-A2.1 Monochain Transgenic H-2Dbβ2m Double Knockout Mice.,”Journal of Experimental Medicine, vol. 185, No. 12, pp. 2043-2051 (1997).
Steinmetz, Michael et al: “Recent experiments with MHC knock-out mice: More questions than answers,”BioEssays, vol. 15, No. 9, pp. 613-615 (1993).
Vitiello, Antonella et al., “Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBC Infection,”Journal of Clinical Investigation, vol. 95, pp. 341-449 (1995).
Vitiello, Antonella et al., “Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatability Complex.,”Journal of Experimental Medicine, vol. 173, No. 4, pp. 1007-1015 (1991).
Wentworth, Peggy A., et al., “Differences and similarities in the A2-1 restricted cytotoxic T Cell repertoire in humans and human leukocyte antigen-transgenic mice,”European Journal of Immunology, vol. 29, No. 1 pp. 97-100 (1996).
U.S. Appl. No. 10/566,386, filed Jan. 30, 2006, as the national stage of PCT/IB2004/002374, filed on Jul. 5, 2004 (which published as WO 2005/004592 A2 on Jan. 20, 2005).
Auriault Claude
Lemonnier François
Lone Yu-Chun
Pajot Anthony
Pancre Veronique
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Hiriyanna Kelaginamane
Institut Pasteur
Kelly Robert M.
LandOfFree
Transgenic mice having a human major histocompatability... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mice having a human major histocompatability..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mice having a human major histocompatability... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4153858